ANN ARBOR, Mich., Feb. 11, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will speak at the 13th Annual BIO CEO & Investor Conference in the Park South wing of the Waldorf-Astoria Hotel on February 15 from 10:00-10:25 AM ET.

BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The meeting provides a forum for institutional investors, industry analysts and senior biotechnology executives to network and present updates on clinical progress, key business issues, and important developments in the biotechnology field. This year's conference will take place from February 14-15 in the Waldorf-Astoria Hotel in New York City.

The presentation will be webcast live and will also be accessible in archive through May 16, 2011, beginning one hour after the presentation. The URL for live and archived access to the presentation is http://www.veracast.com/webcasts/bio/ceoinvestor2011/61205369.cfm. Participants should allow approximately five to ten minutes prior to the presentation start time to visit the site and download any streaming media software needed to listen to the webcast.

About Aastrom Biosciences

Aastrom Biosciences is developing expanded autologous cellular therapies for use in the treatment of severe, chronic cardiovascular diseases. The company's proprietary cell-processing technology enables the manufacture of mixed-cell therapies expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced its cell therapies into late-stage clinical development, including a planned Phase 3 clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical trials in patients with dilated cardiomyopathy. For more information, please visit Aastrom's website at www.aastrom.com.

The Aastrom Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3663

This document contains forward-looking statements, including without limitation, statements concerning clinical trial plans and progress, objectives and expectations, clinical activity timing, intended product development, the performance and contribution of certain individuals and expected timing of collecting and analyzing treatment data, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory approval requirements, competitive developments, and the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. These forward looking statements reflect management's current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.
CONTACT:  Media and investor contact          Stephen Zoegall          Berry & Company          212 253-8881          ir@aastrom.com          szoegall@berrypr.com

company logo

If you liked this article you might like

Why Aastrom Biosciences (ASTM) Stock Is Soaring Today

Rev Shark: Market Chaos Theory

5 Stocks Under $10 Set to Soar

Biotech 2013 by the Numbers: A Blockbuster Year

Contrarian Ideas: Hedge Funds Are Selling These 10 Stocks Trading Below Target Price